-$0.34 EPS Expected for Sangamo Therapeutics, Inc. (NASDAQ:SGMO) This Quarter

Equities research analysts predict that Sangamo Therapeutics, Inc. (NASDAQ:SGMO) will report earnings per share (EPS) of ($0.34) for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Sangamo Therapeutics’ earnings, with the lowest EPS estimate coming in at ($0.38) and the highest estimate coming in at ($0.28). Sangamo Therapeutics posted earnings per share of ($0.01) during the same quarter last year, which suggests a negative year-over-year growth rate of 3,300%. The business is scheduled to announce its next earnings report on Wednesday, November 3rd.

According to Zacks, analysts expect that Sangamo Therapeutics will report full year earnings of ($1.32) per share for the current fiscal year, with EPS estimates ranging from ($1.43) to ($1.11). For the next year, analysts expect that the business will report earnings of ($1.39) per share, with EPS estimates ranging from ($1.94) to ($0.15). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that cover Sangamo Therapeutics.

Sangamo Therapeutics (NASDAQ:SGMO) last issued its quarterly earnings results on Thursday, August 5th. The biopharmaceutical company reported ($0.33) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.03). Sangamo Therapeutics had a negative net margin of 98.21% and a negative return on equity of 27.99%. The firm had revenue of $27.87 million for the quarter, compared to the consensus estimate of $29.72 million.

A number of equities research analysts have weighed in on the stock. Zacks Investment Research cut shares of Sangamo Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 9th. HC Wainwright started coverage on shares of Sangamo Therapeutics in a research report on Thursday, August 26th. They set a “buy” rating and a $25.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and three have given a buy rating to the stock. According to MarketBeat.com, Sangamo Therapeutics currently has an average rating of “Hold” and an average target price of $20.80.

SGMO stock traded up $0.09 during midday trading on Friday, hitting $8.92. 21,194 shares of the stock traded hands, compared to its average volume of 1,135,135. The stock’s fifty day simple moving average is $9.56 and its 200-day simple moving average is $10.53. Sangamo Therapeutics has a 1-year low of $8.60 and a 1-year high of $19.43. The firm has a market cap of $1.30 billion, a P/E ratio of -9.29 and a beta of 1.66.

Institutional investors and hedge funds have recently made changes to their positions in the business. Morgan Stanley increased its holdings in Sangamo Therapeutics by 24.7% during the 2nd quarter. Morgan Stanley now owns 891,147 shares of the biopharmaceutical company’s stock worth $10,667,000 after purchasing an additional 176,775 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of Sangamo Therapeutics by 4.7% during the second quarter. Wells Fargo & Company MN now owns 690,197 shares of the biopharmaceutical company’s stock worth $8,261,000 after acquiring an additional 31,242 shares in the last quarter. Fort Sheridan Advisors LLC lifted its position in shares of Sangamo Therapeutics by 2.3% during the second quarter. Fort Sheridan Advisors LLC now owns 77,680 shares of the biopharmaceutical company’s stock worth $930,000 after acquiring an additional 1,735 shares in the last quarter. Invesco Ltd. lifted its position in shares of Sangamo Therapeutics by 5.9% during the second quarter. Invesco Ltd. now owns 801,873 shares of the biopharmaceutical company’s stock worth $9,599,000 after acquiring an additional 44,410 shares in the last quarter. Finally, Metropolitan Life Insurance Co NY raised its position in shares of Sangamo Therapeutics by 108,530.3% in the second quarter. Metropolitan Life Insurance Co NY now owns 35,848 shares of the biopharmaceutical company’s stock worth $429,000 after buying an additional 35,815 shares in the last quarter. 52.41% of the stock is currently owned by hedge funds and other institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc is a clinical stage biotechnology company, which engages in the research and development of zinc finger proteins. It focuses on three therapeutic areas: inherited metabolic diseases, central nervous system, and diseases and immunology, which comprises inflammatory and autoimmune diseases.

See Also: What is a Reverse Stock Split?

Get a free copy of the Zacks research report on Sangamo Therapeutics (SGMO)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.